Experimental Drug Access Push Won’t Slow Approvals, FDA Says

April 10, 2019

A Food and Drug Administration (FDA) effort to encourage more drug companies to offer unproven therapies to terminally ill patients could steer patients away from another new model without agency oversight.

Related Stories